Literature DB >> 8147888

Inhibition of matrix metalloproteinases by peptidyl hydroxamic acids.

S Odake1, Y Morita, T Morikawa, N Yoshida, H Hori, Y Nagai.   

Abstract

Synthetic inhibitors of interstitial collagenase, tri- and tetrapeptidyl hydroxamic acids, have been developed and tested for their inhibitory activities against human matrix metalloproteinases. A water soluble inhibitor, p-NH2-Bz-Gly-Pro-D-Leu-D-Ala-NHOH (FN-439) inhibited interstitial and granulocyte collagenases, granulocyte gelatinase and skin fibroblast stromelysin with IC50 of 1 x 10(-6) M, 3.0 x 10(-5) M and 1.5 x 10(-4), respectively, but not thermolysin and serine proteinases. FN-439 was found to retain its inhibitory activity against matrix metalloproteinases even after prolonged incubation with pronase or human granulocyte elastase, indicating a favorite candidate of the inhibitor to modulate metalloproteinase activities in vivo.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8147888     DOI: 10.1006/bbrc.1994.1392

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  20 in total

1.  Extracellular matrix plasticity and GABAergic inhibition of prefrontal cortex pyramidal cells facilitates relapse to heroin seeking.

Authors:  Michel C Van den Oever; Bart R Lubbers; Natalia A Goriounova; Ka W Li; Roel C Van der Schors; Maarten Loos; Danai Riga; Joost Wiskerke; Rob Binnekade; M Stegeman; Anton N M Schoffelmeer; Huibert D Mansvelder; August B Smit; Taco J De Vries; Sabine Spijker
Journal:  Neuropsychopharmacology       Date:  2010-06-30       Impact factor: 7.853

2.  Role of matrix metalloproteinases in the acquisition and reconsolidation of cocaine-induced conditioned place preference.

Authors:  Travis E Brown; Melissa R Forquer; Davelle L Cocking; Heiko T Jansen; Joseph W Harding; Barbara A Sorg
Journal:  Learn Mem       Date:  2007-03-09       Impact factor: 2.460

Review 3.  Matrix metalloproteinases. Novel targets for directed cancer therapy.

Authors:  A E Yu; R E Hewitt; E W Connor; W G Stetler-Stevenson
Journal:  Drugs Aging       Date:  1997-09       Impact factor: 3.923

4.  Human breast cancer cells activate procollagenase-1 and invade type I collagen: invasion is inhibited by all-trans retinoic acid.

Authors:  U Benbow; M P Schoenermark; K A Orndorff; A L Givan; C E Brinckerhoff
Journal:  Clin Exp Metastasis       Date:  1999-05       Impact factor: 5.150

5.  Inhibition of matrix metalloproteinase activity disrupts reconsolidation but not consolidation of a fear memory.

Authors:  Travis E Brown; Adrianne R Wilson; Davelle L Cocking; Barbara A Sorg
Journal:  Neurobiol Learn Mem       Date:  2008-10-23       Impact factor: 2.877

6.  Localization of matrix metalloproteinase 9 to the cell surface provides a mechanism for CD44-mediated tumor invasion.

Authors:  Q Yu; I Stamenkovic
Journal:  Genes Dev       Date:  1999-01-01       Impact factor: 11.361

7.  Matrix metalloprotease 1a deficiency suppresses tumor growth and angiogenesis.

Authors:  C J Foley; M Fanjul-Fernández; A Bohm; N Nguyen; A Agarwal; K Austin; G Koukos; L Covic; C López-Otín; A Kuliopulos
Journal:  Oncogene       Date:  2013-05-27       Impact factor: 9.867

8.  Delayed matrix metalloproteinase inhibition reduces intracerebral hemorrhage after embolic stroke in rats.

Authors:  Jean-Christophe Copin; Paolo Merlani; Taku Sugawara; Pak H Chan; Yvan Gasche
Journal:  Exp Neurol       Date:  2008-06-09       Impact factor: 5.330

9.  Matrix metalloproteinase-1 promotes prostate tumor growth and metastasis.

Authors:  Sai Murali Krishna Pulukuri; Jasti S Rao
Journal:  Int J Oncol       Date:  2008-04       Impact factor: 5.650

10.  Atherosclerosis and matrix metalloproteinases: experimental molecular MR imaging in vivo.

Authors:  Vardan Amirbekian; Juan Gilberto S Aguinaldo; Smbat Amirbekian; Fabien Hyafil; Esad Vucic; Marc Sirol; David B Weinreb; Soizic Le Greneur; Eric Lancelot; Claire Corot; Edward A Fisher; Zorina S Galis; Zahi A Fayad
Journal:  Radiology       Date:  2009-05       Impact factor: 11.105

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.